Cardiol Therapeutics Inc.
CRDLDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
8dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
CRDL Earnings Report
EPS Est: $-0.09 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CardiolRx | Phase 3 | Acute Myocarditis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cardiol Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Cardiol Therapeutics Inc.'s (CRDL) pipeline across Phase 3. Its lead program is CardiolRx (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cardiol Therapeutics Inc.'s next FDA catalyst?→
Cardiol Therapeutics Inc.'s (CRDL) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRDL biotech catalysts?→
Add CRDL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cardiol Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.